INFLUENCE OF VARIOUS CYTOKINES ON THE INTERLEUKIN-2-DEPENDENT LYSIS OF MELANOMA-CELLS IN-VITRO

被引:2
作者
SCHULTZ, ES
DUMMER, R
BECKER, JC
ZILLIKENS, D
BURG, G
机构
[1] UNIV ZURICH,SCH MED,DEPT DERMATOL,CH-8091 ZURICH,SWITZERLAND
[2] UNIV WURZBURG,SCH MED,DEPT DERMATOL,D-97080 WURZBURG,GERMANY
关键词
MELANOMA; INTERLEUKIN-2; INTERFERON; TUMOR NECROSIS FACTOR; CYTOKINES;
D O I
10.1007/BF00370730
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
To obtain information about useful combinations of various cytokines in meIanoma therapy,,ve studied the influence of interleukin-2 (IL-2) in combination with interferon-alpha (IFN-alpha), IFN-gamma and tumour necrosis factor-alpha (TNF-alpha) on the lytic activity of IL-2-stimulated cells in vitro. Peripheral mononuclear cells (PMC) were incubated for 4 days with various combinations of cytokines and used as effector cells. Two different melanoma cell lines (M19 and M26) were used as target cells. The lytic activity of stimulated PMC was determined using a modified hexosaminidase assay. IL-2 was mainly responsible for the lytic activity of the effector cells in a dose-dependent manner. IFN-alpha, IFN-gamma and TNF-alpha did not enhance lytic activity with an optimal IL-2 dose (50 IU/ml IL-2). Using a suboptimal TL-2 dose (5 IU/ml), they increased cytotoxicity. The specific lysis of M19 cells was significantly increased by pretreatment of the cells with 5 IU/ml IFN-alpha together with 50 IU/ml TNF-alpha (t-test, P less than or equal to 0.001), while the specific lysis of M26 cells was increased by pretreatment with 5 IU/ml IFN-gamma. We conclude that the lysis of melanoma cells by cytotoxic cells in vitro can be enhanced by various cytokines. The optimal cytokine combination differed for the two melanoma cen lines tested.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 22 条
[1]   HOME THERAPY WITH RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED HUMAN MALIGNANCIES [J].
ATZPODIEN, J ;
KORFER, A ;
FRANKS, CR ;
POLIWODA, H ;
KIRCHNER, H .
LANCET, 1990, 335 (8704) :1509-1512
[2]  
BERGMANN L, 1989, EUR J CANCER CLIN ON, V25, pS31
[3]  
BERGMANN L, 1990, NAT IMMUN CELL GROW, V9, P265
[4]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[5]  
CHOUAIB S, 1991, NOUV REV FR HEMATOL, V33, P471
[6]  
DEFRIES RU, 1988, J IMMUNOL, V140, P3686
[7]  
GARBE C, 1990, J INVEST DERMATOL, V95, P231
[8]   PHASE-I STUDY OF INTERLEUKIN-2 AND INTERFERON ALFA-2A AS OUTPATIENT THERAPY FOR PATIENTS WITH ADVANCED MALIGNANCY [J].
HIRSH, M ;
LIPTON, A ;
HARVEY, H ;
GIVANT, E ;
HOPPER, K ;
JONES, G ;
ZEFFREN, J ;
LEVITT, D .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) :1657-1663
[9]   LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS - INTERFERON-GAMMA SYNERGIZES WITH INTERLEUKIN-2 TO INDUCE LAK CYTOTOXICITY IN HOMOGENEOUS LEUKEMIC PREPARATIONS [J].
KAUFMANN, Y ;
DAVIDSOHN, J ;
LEVANON, M ;
ICEKSON, I ;
REVEL, M ;
RAMOT, B .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 58 (02) :278-288
[10]  
KRUGER S, 1990, J INVEST DERMATOL, V95, P476